Saira Ramasastry Sells 10,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Director Saira Ramasastry sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction on Friday, June 21st. The stock was sold at an average price of $13.19, for a total transaction of $131,900.00. Following the transaction, the director now directly owns 40,485 shares of the company’s stock, valued at $533,997.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Day One Biopharmaceuticals Stock Down 1.0 %

DAWN stock opened at $13.40 on Wednesday. The company has a market cap of $1.17 billion, a PE ratio of -5.34 and a beta of -1.52. The business has a 50-day simple moving average of $14.65 and a 200 day simple moving average of $14.75. Day One Biopharmaceuticals, Inc. has a 52 week low of $9.67 and a 52 week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). On average, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.69 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, May 7th. Needham & Company LLC reissued a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, June 19th. The Goldman Sachs Group reduced their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Piper Sandler reissued an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $37.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DAWN. Charles Schwab Investment Management Inc. raised its stake in Day One Biopharmaceuticals by 38.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock valued at $5,486,000 after purchasing an additional 125,050 shares in the last quarter. Citigroup Inc. raised its stake in Day One Biopharmaceuticals by 4.4% during the third quarter. Citigroup Inc. now owns 100,665 shares of the company’s stock worth $1,235,000 after acquiring an additional 4,234 shares in the last quarter. Deutsche Bank AG raised its stake in Day One Biopharmaceuticals by 5.5% during the third quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after acquiring an additional 9,219 shares in the last quarter. Trexquant Investment LP acquired a new position in Day One Biopharmaceuticals during the third quarter worth about $1,201,000. Finally, Schonfeld Strategic Advisors LLC raised its stake in Day One Biopharmaceuticals by 18.3% during the third quarter. Schonfeld Strategic Advisors LLC now owns 136,700 shares of the company’s stock worth $1,677,000 after acquiring an additional 21,182 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.